IMTX

Immatics N.V

9.36

Aug 27 • 3:59 PM ET -0.07 (-0.74%)

9.86

Aftermarket • 6:46 PM ET +0.50 (5.34%)

Healthcare Biotechnology Germany Small NASD

Aug 25, 7:05 AMImmatics announces a $150 million underwritten offering of ordinary shares and pre-funded warrants priced at $8.69 per share.

Peers: IDYA RCUS TNGX CGON KYMR BMRN CRNX RYTM INCY AXSM

| Held by: SPDW KOMP CANC SBIO ONEQ GWX BBC TMED RFLR KBFR

Scroll to Statements

Index	-
Market Cap	1.40B
Enterprise Value	967.58M
Income	-240.92M
Sales	48.60M
Book/sh	3.34
Cash/sh	3.01
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	407
IPO	Dec 12, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	28.82
P/B	2.80
P/C	3.11
P/FCF	-
EV/EBITDA	-
EV/Sales	19.91
Quick Ratio	7.54
Current Ratio	7.54
Debt/Eq	0.04
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	-1.85
EPS next Y	-2.20
EPS next Q	-0.53
EPS this Y	-12.82%
EPS next Y	-4.11%
EPS next 5Y	-0.80%
EPS past 3/5Y	- 18.43%
Sales past 3/5Y	-33.07% 8.86%
EPS Y/Y TTM	-164.71%
Sales Y/Y TTM	-65.40%
EPS Q/Q	18.96%
Sales Q/Q	98.02%
Earnings	Aug 18 BMO
EPS/Sales Surpr.	-10.59% 0.78%

Insider Own	16.35%
Insider Trans	3.66%
Inst Own	64.47%
Inst Trans	-5.29%
ROA	-39.45%
ROE	-48.08%
ROIC	-51.20%
Gross Margin	-
Oper. Margin	-555.60%
Profit Margin	-495.72%
SMA20	0.70%
SMA50	-0.87%
SMA200	-6.62%
Trades

Shs Outstand	136.69M
Shs Float	125.18M
Short Float	3.93%
Short Ratio	10.35
Short Interest	4.92M
52W High	12.41 -24.58%
52W Low	5.05 85.35%
Volatility	6.26% 5.32%
ATR (14)	0.50
RSI (14)	50.99
Beta	1.33
Rel Volume	1.56
Avg Volume	475.38K
Volume	742,950

Perf Week	9.47%
Perf Month	4.12%
Perf Quarter	-18.25%
Perf Half Y	-7.60%
Perf YTD	-10.86%
Perf Year	73.33%
Perf 3Y	-23.59%
Perf 5Y	-22.39%
Perf 10Y	-
Recom	1.00
Target Price	17.71
Prev Close	9.43
Price	9.36
Change %	-0.74%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-28-26	Initiated	TD Cowen	Buy
Mar-16-26	Resumed	Jefferies	Buy
Sep-18-25	Initiated	Guggenheim	Buy	$16
May-28-25	Initiated	Deutsche Bank	Buy	$10
Oct-07-24	Initiated	Piper Sandler	Overweight	$19
Nov-02-23	Initiated	Cantor Fitzgerald	Overweight
Mar-31-23	Initiated	Mizuho	Buy	$12
Mar-24-23	Initiated	Bryan Garnier	Buy	$16
Nov-20-20	Initiated	BofA Securities	Buy	$13
Sep-22-20	Initiated	Goldman	Buy	$17
Jul-27-20	Initiated	SVB Leerink	Outperform	$17
Jul-24-20	Initiated	Jefferies	Buy

Show Previous Ratings

Aug-25-26 07:00AM	Immatics Announces $150 Million Underwritten Offering (GlobeNewswire) +6.33%
Aug-18-26 07:06AM	Immatics: Q2 Earnings Snapshot (Associated Press)
07:00AM	Immatics Announces Second Quarter 2026 Financial Results and Business Update (GlobeNewswire)
Jul-17-26 10:25AM	Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026 (GlobeNewswire)
Jun-01-26 08:00AM	Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting (GlobeNewswire)
09:00AM	Loading…
May-31-26 09:00AM	Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer (GlobeNewswire)
May-30-26 08:00AM	Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting (GlobeNewswire)
May-12-26 07:17AM	Immatics: Q1 Earnings Snapshot (Associated Press)
07:00AM	Immatics Announces First Quarter 2026 Financial Results and Business Update (GlobeNewswire)
Apr-21-26 10:26AM	Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting (GlobeNewswire)
Apr-17-26 03:00PM	PRAME-directed Cell Therapy Using Immatics' TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma (GlobeNewswire)
Mar-05-26 07:30AM	Immatics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Immatics Announces Full Year 2025 Financial Results and Business Update (GlobeNewswire)
Mar-02-26 05:35PM	Nuvation Bio Inc. (NUVB) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-25-26 07:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Loading…
Dec-11-25 07:00AM	Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress (GlobeNewswire)
Dec-05-25 06:00AM	Immatics Announces $125 Million Underwritten Offering (GlobeNewswire) -14.24%
Nov-18-25 09:40AM	Company News for Nov 18, 2025 (Zacks) +8.98%
Nov-17-25 08:15AM	Immatics (IMTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -7.16%
07:13AM	Immatics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Immatics Announces Third Quarter 2025 Financial Results and Business Update (GlobeNewswire)
Nov-14-25 09:10AM	CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Nov-13-25 08:45AM	Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -6.47%
Nov-12-25 08:30AM	Opus Genetics, Inc. (IRD) Reports Q3 Loss, Beats Revenue Estimates (Zacks) +16.10%
07:00AM	Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps (GlobeNewswire)
Nov-06-25 08:30AM	Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Nov-05-25 08:25AM	Geron (GERN) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-04-25 08:35AM	Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Oct-27-25 07:00AM	Immatics Appoints Amie Krause as Chief People Officer (GlobeNewswire)
Oct-20-25 10:30AM	Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium (GlobeNewswire) +11.04%
07:00AM	Loading…
Oct-01-25 07:00AM	Immatics Appoints Venkat Ramanan as Chief Financial Officer (GlobeNewswire) +5.63%
Aug-18-25 06:12AM	New Strong Sell Stocks for August 15th (Zacks)
Aug-13-25 08:15AM	Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:32AM	Immatics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Immatics Announces Second Quarter 2025 Financial Results and Business Update (GlobeNewswire)
Aug-11-25 06:55PM	Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-07-25 05:10PM	Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates (Zacks)
Jul-09-25 10:30AM	Here Is What You Need To Know Before Investing In Immatics N.V. (IMTX) (Insider Monkey)
Jun-03-25 09:55AM	Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect? (Zacks)
May-31-25 08:00AM	Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma (GlobeNewswire)
May-13-25 07:00AM	Immatics Announces First Quarter 2025 Financial Results and Business Update (GlobeNewswire)
May-12-25 07:35AM	ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +7.55%
May-08-25 05:25PM	Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-06-25 05:25PM	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -10.00%
Apr-23-25 10:00AM	Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting (GlobeNewswire)
Apr-16-25 10:04AM	Is Immatics (NASDAQ:IMTX) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey) -5.95%
Apr-02-25 03:37PM	Is Immatics (IMTX) the Best German Stock to Buy According to Hedge Funds? (Insider Monkey)
Mar-28-25 01:02PM	Immatics N.V.: Trading Below Cash, But Not Without Reason (Seeking Alpha)
Mar-27-25 07:00AM	Immatics Announces Full Year 2024 Financial Results and Business Update (GlobeNewswire)
Nov-19-24 07:25AM	Immatics Sees Revenue Surge Despite R&D Expenses (TipRanks)
Nov-18-24 07:00AM	Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER IMA402 Targeting PRAME (GlobeNewswire)
Nov-08-24 05:00PM	Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME (GlobeNewswire)
Oct-11-24 06:57AM	Immatics Advances IMA203 to Phase 3 Trial in Melanoma (TipRanks)
Oct-10-24 08:50PM	Immatics Announces Pricing of $150 Million Public Offering (GlobeNewswire) -15.58%
07:30AM	Immatics Announces Proposed $150 Million Public Offering (GlobeNewswire)
06:30AM	Immatics Announces Updated Phase 1b Clinical Data on ACTengine IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial (GlobeNewswire)
Oct-09-24 08:03AM	Immatics N.V. (IMTX) Receives Buy Rating from Analysts (Insider Monkey)
Oct-04-24 09:00AM	Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024 (GlobeNewswire)
Sep-16-24 05:25AM	Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update (GlobeNewswire)
Sep-06-24 07:00AM	Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024 (GlobeNewswire)
Aug-13-24 07:00AM	Immatics Announces Second Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Jul-31-24 07:00AM	Immatics Appoints Alise Reicin to Board of Directors (GlobeNewswire)
Jul-18-24 09:00AM	Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024 (GlobeNewswire)
Jul-08-24 07:00AM	Memo Therapeutics AG appoints Paul Carter as Chairperson (GlobeNewswire)
May-14-24 08:15AM	Immatics (IMTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.45%
07:00AM	Immatics Announces First Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Mar-21-24 02:52PM	IMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -5.89%
07:00AM	Immatics Announces Full Year 2023 Financial Results and Corporate Update (GlobeNewswire)
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Jan-17-24 08:30PM	Immatics Announces Pricing of $175 Million Public Offering (GlobeNewswire) -7.36%
04:01PM	Immatics Announces Proposed Public Offering (GlobeNewswire)
Jan-16-24 03:59AM	DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing (PR Newswire)
Nov-30-23 04:00AM	Levicept Appoints Eliot Forster as CEO (GlobeNewswire)
Nov-14-23 07:00AM	Immatics Announces Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Nov-08-23 07:00AM	Immatics Reports Interim Clinical Data from ACTengine IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial (GlobeNewswire)
Oct-24-23 07:00AM	Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine IMA203 TCR-T Monotherapy (GlobeNewswire)
Sep-12-23 06:50AM	Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors (PR Newswire)
Sep-11-23 07:00AM	Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics (ACCESSWIRE)
Aug-17-23 07:00AM	Immatics Announces Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Aug-10-23 07:00AM	Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors (GlobeNewswire)
Jul-24-23 07:00AM	Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb (GlobeNewswire)
May-16-23 07:00AM	Immatics Announces First Quarter 2023 Financial Results and Business Update (GlobeNewswire)
May-02-23 07:00AM	Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME (GlobeNewswire) +27.46%
May-01-23 07:00AM	Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration (GlobeNewswire)
Apr-23-23 08:56AM	TipRanks Perfect 10 List: These 2 Top-Rated Stocks Could Be Long-Term Winners (TipRanks)
Mar-21-23 07:31AM	Immatics Announces Full Year 2022 Financial Results and Corporate Update (GlobeNewswire)
Nov-17-22 07:00AM	Immatics Announces Third Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Oct-10-22 07:37AM	Immatics Announces $110 Million Underwritten Offering of Ordinary Shares (GlobeNewswire) +11.60%
07:36AM	Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME (GlobeNewswire)
Sep-10-22 03:06AM	Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022 (GlobeNewswire)
Aug-23-22 07:00AM	Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME (GlobeNewswire)
Aug-09-22 07:00AM	Immatics Announces Second Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Jun-25-22 10:42AM	Do Its Financials Have Any Role To Play In Driving Immatics N.V.'s (NASDAQ:IMTX) Stock Up Recently? (Simply Wall St.)
Jun-07-22 07:00AM	Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer (GlobeNewswire)
Jun-02-22 07:05AM	Immatics Announces First Quarter 2022 Financial Results and Business Update (GlobeNewswire)
06:59AM	Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs (GlobeNewswire)
May-26-22 06:54AM	What Kind Of Shareholders Own Immatics N.V. (NASDAQ:IMTX)? (Simply Wall St.)
May-18-22 07:00AM	Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors (GlobeNewswire)
May-10-22 07:00AM	Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors (GlobeNewswire)
May-03-22 11:41AM	Immatics (NASDAQ:IMTX) shareholders have endured a 37% loss from investing in the stock a year ago (Simply Wall St.)

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics. The company was founded on March 10, 2020, and is headquartered in Tuebingen, Germany.

CEODr. Harpreet Singh Ph.D.

Chief Financial OfficerDr. Venkat Ramanan Ph.D.

Chief People OfficerMs. Amie Krause

Co-Founder & Member of the Scientific Advisory BoardDr. Hans-Georg Rammensee Ph.D.

Co-Founder & Chief Innovation OfficerDr. Toni Weinschenk Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PERCEPTIVE ADVISORS LLC	Director	Aug 26 '26	Buy	8.69	863,060	7,499,991	11,246,516	Aug 27 04:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMTX

Immatics N.V

Upgrade your Finviz experience